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Fluoxetine and thioridazine inhibit 
efflux and attenuate crystalline 
biofilm formation by Proteus 
mirabilis
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Barnes1, Bhavik A. Patel  1, Khondaker M. Rahman  3, Mark J. Sutton4 & Brian V. Jones  1
Proteus mirabilis forms extensive crystalline biofilms on indwelling urethral catheters that block urine 
flow and lead to serious clinical complications. The Bcr/CflA efflux system has previously been identified 
as important for development of P. mirabilis crystalline biofilms, highlighting the potential for efflux 
pump inhibitors (EPIs) to control catheter blockage. Here we evaluate the potential for drugs already 
used in human medicine (fluoxetine and thioridazine) to act as EPIs in P. mirabilis, and control crystalline 
biofilm formation. Both fluoxetine and thioridazine inhibited efflux in P. mirabilis, and molecular 
modelling predicted both drugs interact strongly with the biofilm-associated Bcr/CflA efflux system. 
Both EPIs were also found to significantly reduce the rate of P. mirabilis crystalline biofilm formation 
on catheters, and increase the time taken for catheters to block. Swimming and swarming motilies in 
P. mirabilis were also significantly reduced by both EPIs. The impact of these drugs on catheter biofilm 
formation by other uropathogens (Escherichia coli, Pseudomonas aeruginosa) was also explored, and 
thioridazine was shown to also inhibit biofilm formation in these species. Therefore, repurposing of 
existing drugs with EPI activity could be a promising approach to control catheter blockage, or biofilm 
formation on other medical devices.
Indwelling urethral catheters (IUC) are widely used for long-term bladder management in both community and 
nursing home settings, and can provide significant improvement to quality of life for many patients. However, the 
care of individuals undergoing long-term catheterisation is frequently undermined by acquisition of infection 
(catheter associated urinary tract infection; CAUTI). Proteus mirabilis is a particularly problematic and prevalent 
pathogen in this regard, and this species is amongst the most commonly isolated from CAUTI1,2. Colonisation 
of the catheterised urinary tract by P. mirabilis is also associated with the onset of serious clinical complications, 
stemming from its ability to form unusual crystalline structures on catheter surfaces, which can damage tissues 
and block urine flow1–3.
The encrustation and blockage of catheters by P. mirabilis is attributable to its ability to form extensive biofilm 
communities on catheter surfaces, coupled with the production of a potent urease enzyme that hydrolyses urea 
and forms ammonia4–7. The generation of ammonia via ureolysis leads to a rapid rise in urinary pH and in the 
resulting alkaline conditions, normally soluble components of urine, precipitate and form crystals of ammonium 
magnesium phosphate (struvite) and calcium phosphate (hydroxyapatite)2,4,7–10. These crystals become trapped 
in the growing biofilm matrix and are incorporated into its structure2,4. The action of the P. mirabilis urease 
also generates a highly alkaline microenvironment within biofilms, while the exopolymeric matrix encasing bio-
film cells can attract and bind calcium and magnesium ions, which collectively serve to accelerate and stabilise 
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biofilm-associated crystal growth11,12. Ultimately these processes result in the extensive mineralisation of biofilms, 
and the development of crystalline biofilm structures which obstruct urine flow2–4.
Because the majority of patients undergoing long-term catheterisation are cared for outside the hospital 
environment where continual clinical monitoring is not available, catheter blockage is often not noticed until 
more serious consequential complications arise3. A particular hazard of catheter blockage is the accumulation of 
infected urine in the bladder, which eventually results in reflux to the upper urinary tract and subsequent onset of 
pyelonephritis, septicaemia, and shock3,13. It has been estimated that ~50% of individuals undergoing long-term 
catheterisation will suffer from catheter blockage at some point during their care, with a considerable proportion 
experiencing repeated and chronic blockage3,14. It is perhaps then unsurprising that blockage is also the cause of 
numerous emergency hospital referrals, and not only damages the health of patients, but also places significant 
strain on healthcare resources3,15.
Although a range of catheter types have been developed in attempts to combat CAUTI, all remain susceptible 
to P. mirabilis encrustation and are of no value in the long-term setting3,16,17. These include catheters with antimi-
crobial coatings such as nitrofurazone and silver, which have been found to be ineffective in preventing CAUTI 
even during short-term use18. Furthermore, once P. mirabilis colonises the catheterised urinary tract it is exceed-
ingly difficult to eradicate, and can persist through numerous catheter changes and antibiotic treatments, result-
ing in chronic infections and recurrent blockage in some patients19. Currently, there are no fully effective methods 
for control of P. mirabilis CAUTI and associated blockage, and further work in this area is urgently needed.
Recently, we demonstrated that efflux systems are important in the formation of P. mirabilis crystalline bio-
films, and P. mirabilis mutants with disruptions in the Bcr/CflA efflux system (a member of the Major Facilitator 
Superfamily of transporters) were found to be significantly attenuated in ability to form crystalline biofilms 
and block catheters20. This raises the potential for efflux pump inhibitors (EPIs) to provide a novel and effective 
approach to control bacterial biofilm formation in the catheterised urinary tract, and combat catheter block-
age by P. mirabilis. Moreover, licensed drugs already commonly used in human medicine have been shown to 
have potential EPI activity in other bacterial species, and also to reduce biofilm formation through this activ-
ity21–25. Here we tested the selective serotonin re-uptake inhibitor, fluoxetine, and the antipsychotic-drug, thi-
oridazine, for potential EPI activity in P. mirabilis and interaction with the biofilm-associated Bcr/CflA efflux 
system. Subsequently, the capacity of these drugs to attenuate crystalline biofilm formation was evaluated using a 
representative model of the catheterised urinary tract.
Results
Fluoxetine and thioridazine inhibit efflux in Proteus mirabilis. Fluoxetine and thioridazine were 
screened for inhibition of efflux in P. mirabilis strain B4 using an ethidium bromide (EtBr) accumulation assay. 
The proton gradient decoupling agent carbonyl cyanide m-chlorophenyl hydrazine (CCCP) was utilised as a 
general inhibitor of energy-dependent membrane transport, and a positive control for the accumulation assay 
(Fig. 1). Assessment of minimum inhibitory concentrations (MICs) demonstrated an MIC of 256 µg/mL for 
fluoxetine, and 800 µg/mL for thioridazine against P. mirabilis B4. Efflux assays were subsequently conducted 
with concentrations reflecting 0.125x and 0.25x the MIC.
At concentrations tested, both drugs exhibited putative efflux inhibition against P. mirabilis strain B4, as 
indicated by increased cellular fluorescence in treated vs. untreated cells in EtBr accumulation assays (Fig. 1a). 
Fluoxetine generated the greatest increase in cellular fluorescence suggesting a greater level of EtBr efflux inhibi-
tion was achieved with this drug compared to thioridazine (Fig. 1a). A dose-dependent effect was observed for 
fluoxetine, with levels of cellular fluorescence increasing in line with the concentration of the drug tested, but for 
thioridazine both concentrations tested elicited a comparable increase in cellular fluorescence (Fig. 1a). Broadly 
similar results were obtained when these drugs were tested against an extended panel of P. mirabilis clinical 
isolates, with fluoxetine consistently producing a greater increase in cell fluorescence compared to thioridazine 
(Fig. 1b). However, a notable level of strain-strain variability was evident in response to both drugs, and in con-
trast to strain B4, thioridazine generated much more pronounced dose-dependent changes in cell fluorescence 
for most other strains tested (Fig. 1b).
Interaction of thioridazine and fluoxetine with P. mirabilis efflux systems involved in crystal-
line biofilm formation. Using an in silico molecular modelling approach, we evaluated the potential for 
thioridazine and fluoxetine to interact with the Bcr/ClfA efflux system, which we have previously shown to be 
important for P. mirabilis crystalline biofilm formation20. The blind molecular docking study, in which the ligand 
could explore the entire structure of the protein to find probable cavities to bind in, showed the ligands bind to 
the channel region of the transporter (Fig. 2a and Supplementary Figure 4). Interestingly, both ligands occupied 
binding sites close to each other, suggesting a similar mode of inhibition. GOLD flexible molecular docking 
showed that the association between the Bcr/ClfA protein and fluoxetine or thioridazine are favourable, and that 
these associations stabilize the complex by about −33.6 and −40 kcal/mol, respectively. Both drugs are predicted 
to occupy a hydrophobic amino acid rich binding pocket and show strong interaction with Ile26, Phe58, Phe110, 
Val117, Phe138, Tyr307, Val310, Val311, Val313 and Ala314 (Supplementary Figure 5).
Time dependence of root-mean-square deviations (RMSD) (Å) for the backbone atoms relative to the start-
ing structure during 100 ns MD simulations of both ligand-free and ligand-bound Bcr/CflA pump are shown in 
Supplementary Figure 6. It can be seen from the RMSD curves that the Bcr/CfIA-fluoxetine complex showed 
notably more fluctuations during the first 50 ns of the simulation compared to the Bcr/CfIA-thioridazine com-
plex. Both complexes appeared to stabilise and reach a steady state after ~80 ns, indicated by the relatively stable 
RMSD values from 80 ns to the end of the simulations (Supplementary Figure 6). The average structures of each 
complex were extracted from the MD trajectories and analyzed to study the molecular level interaction during 
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the simulations. The orientation and the interaction of the compounds with the key residues within the binding 
site are shown in Fig. 2b,c.
Post MD simulations energy analysis using MM-PBSA/MM-GBSA calculations showed that Bcr/CflA 
-thioridazine, with the energy of binding being −38.6 kcal/mol, formed a more stable and favorable complex com-
pared to the Bcr/CflA-fluoxetine, which showed an energy of binding of −26.7 kcal/mol. Comparison between the 
GB energies, which are calculated in a different way and puts emphasis on the electerostatic components of the 
energy, still showed a notably better energy of binding for the Bcr/CflA-thioridazine complex (−47.74 kcal/mol), 
compared to the Bcr/CflA-fluoxetine complex (−33.95 kcal/mol) (Table 1).
Interaction energies between the ligands and the key residues within the binding site of Bcr/CflA obtained 
from the average structures during the molecular dynamics simulations are listed in the Table 2. The analysis 
showed that fluoxetine showed strong interactions with Gly57, Met338, Val310, and Val311, while thioridazine 
showed very strong interactions with Met22, Phe58, Phe138 and Ser116. These amino acid residues mainly show 
hydrogen bond, Pi-cation, and electrostatic interactions that help to stabilize the complex. The molecular sim-
ulation data suggests that these strong interactions can potentially lead to the inhibition of the Bcr/CflA pump.
Effect of EPI treatment on P. mirabilis crystalline biofilm formation, pH elevation, and survival 
in bladder models. To determine if exposure to thioridazine or fluoxetine could significantly reduce P. 
mirabilis crystalline biofilm formation, and identify any effects on elevation of urinary pH or bacterial viability 
Figure 1. Effect of putative EPIs on accumulation of EtBr in P. mirabilis. The EPI activity of thioridazine and 
fluoxetine was assessed using the EtBr accumulation assay in artificial urine supplemented with 20 mM glucose, 
against the P. mirabilis catheter isolates. Fluorescence intensity relative to cell free controls was measured after 
2 h exposure to EPIs at concentrations (µg/mL) reflecting 0.125x and 0.25x the MIC for each drug against P. 
mirabilis strain B4. Readings from treated cells were compared with untreated controls (No EPI but with EthBr 
substrate), and cells treated with the proton gradient decoupling agent carbonyl cyanide m-chlorophenyl 
hydrazine (CCCP), as a+ve control for the accumulation assay. (a) Results of accumulation assays for 
treatment with CCCP, thioridazine, or fluoxetine. (b) Results of accumulation assays for treatment with CCCP, 
thioridazine, or fluoxetine against a broader panel of P. mirabilis clinical isolates **P < 0.001, ****P < 0.00001 
vs untreated controls. All data represent the mean of 3 replicates. Error bars show standard error of the mean.
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in the model system, these drugs were tested using in vitro infection models of the catheterised urinary tract 
(Supplementary Figure 1; Stickler et al.26). Models simulating an established high-level infection (109 CFU/
mL) were run for a set time (10 h) and levels of crystalline biofilm formation in treated models compared with 
untreated controls (Fig. 3). A significant reduction in encrustation of catheters was evident in models treated 
with thioridazine (Fig. 3b). In contrast, no statistically significant reduction in encrustation was observed for 
catheters taken from fluoxetine-treated models over this length of time, although a general reduction was noted 
on distal sections compared to untreated controls (Fig. 3b). Direct visualisation of crystalline biofilm formation 
by low-vacuum SEM of catheter cross sections were in line with the results of calcium quantification, and also 
demonstrated reduced levels of crystalline deposits for EPI treated catheters, with a marked absence of encrus-
tation on thioridazine treated catheters (Fig. 3c). The elevation of urinary pH was found to be unaffected by EPI 
treatment in these timed model experiments (Fig. 3d), but numbers of viable P. mirabilis cells in residual bladder 
urine showed a significant reduction in models treated with both drugs (Fig. 3e).
Figure 2. Interaction of fluoxetine and thioridazine with the biofilm-associated Bcr/CflA transporter. (a) 
Average 2D and 3D structures of bcr/CflA:thioridazine and bcr/CflA:fluoxetine; Binding sites and key 
interactions between the Bcr/CflA transporter and (b) thioridazine; (c) fluoxetine.
Interaction
Complexa
Bcr/CflA-
Thioridazine
Bcr/CflA-
Fluoxetine
Electrostatic (ΔEele) −9.08(1.31) −8.17(1.33)
van der Waals (ΔEvdw) −51.81(1.42) −36.36(1.99)
Surface energy (ΔEsur) −6.79(0.11) −5.88(0.10)
Solvation energy (ΔEsol) 22.28(2.27) 17.77(1.90)
Polar solvation energy 
(ΔGPB)
−38.60(2.20) −26.75(2.39)
Electrostatic solvation 
energy (ΔGGB)
−47.74(1.60) −33.95(2.18)
Table 1. Average energy contributions to form Bcr/CflA complexes fluoxetine or thioridazine. aInteraction 
energies between complexes of Bcr/CflA and either fluoxetine or thioridazine (kcal/mol). Figures in parentheses 
provide standard error of the mean.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 12222  | DOI:10.1038/s41598-017-12445-w
Impact of EPI treatment on catheter blockage. To determine if effects on crystalline biofilm forma-
tion by fluoxetine or thioridazine translated to a significant extension of catheter life span and a delay in catheter 
blockage, we measured the time taken for catheters to become blocked in in vitro models treated with these drugs, 
compared to untreated controls. Models were used to simulate scenarios of both established high-level infection 
(109 CFU/mL) or early colonisation of the catheterised urinary tract (103 CFU/mL) (Nzakizwanayo et al.27), and 
doubling concentrations of drugs reflecting 0.125x, 0.25x and 0.5x the P. mirabilis B4 MIC were evaluated.
A significant dose-dependent increase in the time taken for catheters to block was observed in thioridazine 
treated models of established infection (Fig. 4a). Fluoxetine was also observed to generate a statistically signifi-
cant increase in time to blockage, but this was less pronounced than that observed for thioridazine, and was only 
evident at the highest concentration tested (0.5x MIC, Fig. 4a). Congruent with these results, treatment of models 
simulating early low-level colonisation of the catheterised urinary tract with the highest doses of thioridazine or 
fluoxetine (0.5x bacterial MIC), produced a commensurately greater increase in time to blockage (Fig. 4b). No 
significant effects of EPI treatment were observed on elevation of urinary pH, or levels of viable cells in residual 
bladder model urine in either established or early stage models at time of blockage, but a trend towards reduced 
viable cell counts at time of blockage with increasing drug concentrations was evident in models of established 
infection treated with thioridazine (Fig. 4a).
Impact of EPI treatment on swimming and swarming motility. Because our previous biofilm for-
mation deficient mutant with disruption in the Bcr/CflA efflux system also displayed considerable reduction 
in motility, we also assessed the impact of thioridazine and fluoxetine treatment on swimming and swarming 
in P. mirabilis. Thioridazine exhibited the greatest impact on both motilities, with concentrations at 0.25x and 
0.5x MIC (200 and 400 µg/mL respectively), almost completely abolishing swarming whilst swimming motility 
was reduced in a dose-dependent manner (Fig. 5a). In contrast, fluoxetine had less effect on both swimming 
and swarming at the concentrations tested. A dose-dependent decrease in swimming motility was evident with 
increasing concentrations of fluoxetine, but while a significant reduction in swarming was noted at 0.5x MIC 
(128 µg/mL), lower concentrations appeared to increase swarming motility (Fig. 5a).
Impact of thiroidazine and fluoxetine treatment on catheter biofilm formation by other urop-
athogens. Because biofilm formation is also a key feature of infections caused by other urinary tract patho-
gens relevant to CAUTI, we also evaluated the potential for thioridazine or fluoxetine to control catheter biofilm 
Complexa Residueb
Interaction energy 
(kJ/mol)c
Bcr/CflA-Thioridazine
Ala 113 −10.64
Arg 134 −14.10
Gln 62 −10.23
Met 22 −24.36
Phe 58 −46.44
Phe 138 −22.06
Phe 255 −6.97
Phe 306 −6.36
Pro 23 −4.33
Ser 19 −9.12
Ser 116 −13.40
Val 311 −7.18
Bcr/CflA-Fluoxetine
Ala 113 −10.61
Ala 114 −10.68
Arg 134 −10.10
Gly 57 −13.58
Ile 55 −11.63
Met 338 −15.03
Phe 56 −10.79
Ser 116 −7.02
Tyr 54 −8.91
Tyr 307 −7.62
Tyr 335 −9.50
Val 310 −16.84
Val 311 −22.41
Table 2. The interaction energies between fluoxetine or thioridazine and important key residues of ligand 
binding site in average structures Bcr/CflA-ligand complexes. aAverage structures of complexes of Bcr/CflA and 
either thioridazine or fluoxetine were extracted from 100 ns molecular dynamics trajectories. bResidues derived 
from average structures. Residues in bold denote those identified in both thioridazine and fluoxetine models. 
cInteraction energies between residues in average structures of Bcr/CflA-ligand complexes.
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formation in two other common uropathogens, Escherichia coli and Pseudomonas aeruginosa, when deployed 
at concentrations inhibiting P. mirabilis efflux and crystalline biofilm formation. Because these species do not 
encrust or block catheters, the impact of EPI treatment was evaluated in timed bladder model experiments (sim-
ulating established infection), and levels of biofilm formation assed by a modified crystal violet assay (Fig. 6). In 
both species thioridazine treatment was able to produce a significant reduction in catheter biofilm on sections 
of catheter proximal to the eye-hole, where the greatest levels of biofilm formation typically occur (Fig. 6a,b). 
In contrast, no significant reduction in biofilm formation was elicited by fluoxetine treatment (Fig. 6a,b). Both 
thioridazine and fluoxetine produced a small but statistically significant reduction in numbers of viable E. coli 
cells in bladder models at concentrations tested, but no similar significant effects were observed for P. aeruginosa 
(Fig. 6c,d). No EPI tested had any influence on pH of artificial urine in these experiments (Fig. 6e,f).
Discussion
We have previously linked efflux activity to crystalline biofilm formation and motility in P. mirabilis, and demon-
strated the importance of the Bcr/CflA MFS transporter to catheter blockage by this organism20. Results obtained 
in this study now provide further evidence that efflux systems are important to the formation of crystalline 
Figure 3. Effect of EPI administration on P. mirabilis crystalline biofilm formation. To investigate the impact 
of EPI treatment on crystalline biofilm formation, timed bladder model experiments were conducted and levels 
of encrustation quantified and visualised at the end of experiments. Models were supplied with standardised 
artificial urine with initial pH of 6.1, and containing EPIs at 0.5x MIC of each drug tested (thioridazine 400 µg/
mL, or fluoxetine 128 µg/mL). Models were inoculated with 109 CFU/mL of P. mirabilis strain B4 (simulating 
established infection), and viable planktonic cells and pH measured in residual bladder after 10 h when models 
were deactivated. Catheters were removed and sectioned for analysis at the 10 h time point. (a) Schematic 
showing catheter sections analysed for levels of encrustation. (b) Quantification of calcium on catheter sections 
by flame photometry as a measure of encrustation. (c) Scanning Electron Microscopy of cross sections adjacent 
to catheter section 1 showing levels of crystalline biofilm formed in control and treated catheters. (d) pH of 
residual bladder urine after 10 h. (e) Number of viable cells present in residual urine after 10 h. Data represent 
a minimum of three replicate experiments. Error bars show standard error of the mean. *P < 0.05 vs control. 
The diagram of catheter section used in part a of this Figure is taken from Holling et al. 2014 Infect Immun 80: 
1616–162620.
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biofilms by P. mirabilis, and confirm that suppression of efflux using chemical inhibitors is a potentially viable 
approach to control biofilm formation in the catheterised urinary tract. The molecular docking study, followed by 
molecular dynamic simulations, also suggests that both drugs evaluated here (fluoxetine and thioridazine) bind 
favorably within the channel region of the biofilm-associated Bcr/CflA transporter, and form stable complexes. 
These interactions are predicted to be strong enough to inhibit the functional mechanism of the transporter, and 
when considered in the context of our previous studies of biofilm formation in Bcr/CflA transposon mutants20, are 
in keeping with the reduction in crystalline biofilm formation observed in bladder models treated with fluoxetine 
or thioridazine.
The overall findings of this study are also congruent with a growing body of evidence supporting a role for 
efflux systems in numerous aspects of bacterial virulence, including in pathogens relevant to CAUTI such as 
P. aeruginosa, E. coli, Staphylococcus aureus, and Klebsiella pneumoniae. These include aspects of survival and 
fitness within the host, ability to initiate infection, survival and replication within host cells, roles related to the 
expression of virulence attributes, and also biofilm formation20,21,23,24,28–36. Perhaps of most relevance to this study 
are investigations of biofilm formation in E. coli and P. aeruginosa, which have identified genes encoding efflux 
systems to be up-regulated during biofilm formation (compared to planktonic cells), among the most highly 
expressed genes in mature biofilms, and have linked the reduced antibiotic susceptibility of biofilms to over 
expression of efflux in these communities23,28,37–39. An EPI-mediated reduction in biofilm formation, including 
through the use of thioridazine, has also previously been reported in E. coli23. Collectively these previous studies 
fit well with the mitigation of biofilm formation we also observed in E. coli and P. aeruginosa with thioridazine 
treatment.
Figure 4. Effect of EPI administration on ability of P. mirabilis to block indwelling urethral catheters. Models 
were supplied with standardised artificial urine with initial pH of 6.1, and EPIs thioridazine and fluoxetine 
were supplied in artificial urine media throughout experiment. Models simulating both established infection 
(inoculated with 109 CFU/mL of P. mirabilis strain B4), or early stages of infection (inoculated with 103 CFU/
mL of P. mirabilis strain B4) were run. Upon blockage viable planktonic cells in residual urine in “bladders” 
were enumerated and pH measured. (a) Impact of EPI treatment on time taken for catheters to block in models 
simulating established infection. Models were treated with concentrations reflecting 0.125x, 0.25x, or 0.5x the 
MIC of each drug (100, 200, 400 µg/mL thioridazine; 32, 64, 128 µg/mL fluoxetine). (b) Impact of EPI treatment 
on time taken for catheters to block in models simulating early stages of infection. Models were treated with 
concentrations reflecting 0.5x MIC values for each drug (400 µg/mL thioridazine, 128 µg/mL fluoxetine). Data 
represent a minimum of three replicate experiments. Error bars show standard error of the mean. ***P < 0.0001 
vs control; ****P < 0.00001 vs control.
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Recent investigations have also pointed to a range of potential mechanisms through which inhibition of efflux 
may impact on biofilm formation. For example, signalling molecules which mediate cell-cell communication, and 
regulate population density dependent processes are substrates for some efflux systems33,40,41. This opens the pos-
sibility for efflux inhibitors to interfere with quorum-sensing and in turn disrupt processes orchestrated by this 
inter-cellular communication system, including biofilm formation. In addition, studies of Pseudomonas syringae 
demonstrate how the accumulation of normally extruded substrates within the cell, resulting from loss of a par-
ticular efflux pump, can alter expression of unexpected gene sets leading to changes in disparate phenotypes42. 
Collectively these observations afford the potential for efflux pumps to contribute to regulation of a wide range 
of traits relevant to virulence and biofilm formation, and indicate that these transporters may perform regulatory 
functions beyond their basic accepted role in cellular detoxification.
Alternatively, it has been proposed that some efflux pumps act as a waste management system during matura-
tion of the biofilm23, allowing the densely packed population of biofilm-associated cells to deal with the inevitable 
build-up of toxic metabolic end products as the biofilm expands. Our previous data from a P. mirabilis Bcr/ClfA 
MFS transporter mutant are well aligned with this theory, and disruption of the Bcr/CflA system led to defects 
and reductions in later stages of biofilm development and expansion, but did not appear to impede early events 
in this process20. While the present study did not specifically examine the effects of thioridazine or fluoxetine on 
distinct stages of biofilm formation, data from timed 10 h bladder model experiments are compatible with poten-
tial effects on biofilm maturation and expansion, and EPI treatments generated similar results to those obtained 
from the defined Bcr/CflA mutant in analogous experiments20. Nevertheless, further investigation will be required 
to understand how efflux inhibition leads to reduced crystalline biofilm formation in P. mirabilis, and currently 
available data do not presently rule out any of the mechanisms described above.
Swarming is a complex multicellular behaviour in P. mirabilis, sharing many characteristics of biofilm for-
mation, and also likely to be regulated by quorum sensing43. Given the almost complete abolition of swarming 
observed in our previous Bcr/CflA efflux mutant20, the strong effects of thioridazine and fluoxetine on swarming 
motility are in keeping with the inhibition of efflux by these drugs, and their predicted interaction with the Bcr/
CflA system. The effects of thioridazine and fluoxetine on swimming motility are also congruent with the con-
siderable reductions in swimming ability observed in our P. mirabilis bcr/ClfA mutant20. Moreover, reductions in 
both swimming and swarming have been noted in other species when efflux systems are disrupted, and linked to 
Figure 5. Effect of EPI treatment on motility. The impact of EPI treatment on swimming and swarming 
motility in strain B4 was evaluated by supplementation of LB agar (1.5% for swarming and 0.15% for 
swimming) with either (a) thioridazine (100, 200 or 400 µg/mL) or (b) fluoxetine (32, 64 or 128 µg/mL). 
Significant differences in motility upon EPI exposure are denoted by changes in distances migrated (mm) 
compared to untreated controls. Data represent the mean of at least 3 replicates, and error bars show standard 
error of the mean. *P < 0.05 vs untreated control; **P < 0.001 vs untreated control; ***P < 0.0001 vs untreated 
control; ****P < 0.00001 vs untreated control.
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aberrations in flagella biosynthesis, and reductions in expression of genes related to motility30,34,42. Although the 
impact of thioridazine or fluoxetine treatment on flagella production in P. mirabilis is yet to be determined, this is 
in keeping with reductions in both swimming and swarming motilities when efflux systems are inhibited, and it is 
a plausible hypothesis that these drugs may influence flagellar production in P. mirabilis as well.
In the context of catheter blockage, both swimming and swarming motilities have been linked with biofilm 
formation and virulence in several uropathogens44,45, and are proposed to contribute to P. mirabilis crystalline 
biofilm formation and CAUTI. However, no concrete role for either motility has yet been established in P. mira-
bilis crystalline biofilm formation specifically, and mutants with defects in motility did not exhibit reduced bio-
film formation in bladder model experiments5. While this does not fully preclude the potential for reductions 
in swimming or swarming to play a part in the attenuation of blockage generated by thioridazine and fluox-
etine, it seems unlikely that this is a major factor in the effect of these drugs on crystalline biofilm formation. 
Nevertheless, motility and particularly swarming is considered to be important in the initial colonisation of the 
catheterised urinary tract5,43, and interventions that can suppress motility in P. mirabilis may have applications in 
preventing colonisation of the catheterised urinary tract.
In contrast to swimming and swarming, the ability to grow and persist under the conditions encountered in 
the catheterised urinary tract, are undoubtedly critical to the pathogenesis of P. mirabilis CAUTI, and the forma-
tion of crystalline biofilms. Although thioridazine and fluoxetine treatment showed no statistically significant 
impact on the numbers of viable cells in bladder models at the end of time-to-blockage experiments, a trend 
towards reduction in viable cell counts was observed as concentrations of thioridazine increased. Moreover, in 
Figure 6. Effect of EPI administration on catheter biofilm formation by other uropathogens. To investigate the 
impact of EPI treatment on biofilm formation by Escherichia coli and Pseudomonas aeruginosa, timed bladder 
model experiments were conducted and levels of biofilm formation quantified at the end of experiments. 
Models were supplied with standardised artificial urine with initial pH of 6.1, and containing EPIs at 0.5x MIC 
of each drug tested (thioridazine 400 µg/mL, or fluoxetine 128 µg/mL). Models were inoculated with 109 CFU/
mL of E. coli or P. aeruginosa (simulating established infection), and viable planktonic cells and pH measured in 
residual bladder after 10 h when models were deactivated. Catheters were removed and sectioned for analysis 
at the 10 h time point as shown in Fig. 6. (a,b) Quantification of biomass on catheter sections using modified 
crystal violet biofilm quantification assay. (c,d) Number of viable cells present in residual urine after 10 h. (e,d) 
pH of residual bladder urine after 10 h. Data represent a minimum of three replicate experiments. Error bars 
show standard error of the mean. *P < 0.05, ** < 0.01 vs control.
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timed models where responses to treatment were evaluated after 10 h, statistically significant reductions in viable 
cells were evident in both fluoxetine and thioridazine treated models.
The reduced cell numbers observed at earlier stages of colonisation or infection in bladder models suggest thi-
oridazine and fluoxetine treatment may also delay blockage by impairing P. mirabilis growth in the bladder model 
system. Although this would seem to conflict with use of these drugs at concentrations well below the established 
MICs (0.5x and below), these MIC values were defined in standard LB broth cultures, and not the specific con-
ditions P. mirabilis must cope with in bladder models. Furthermore, only relatively small impacts on growth in 
bladder models were observed at the concentrations of thioridazine and fluoxetine used in these experiments, 
which is compatible with use at sub-MIC concentrations.
Overall the inhibition of efflux by thioridazine and fluoxetine appears to perturb a range of traits and processes 
relevant to P. mirabilis CAUTI and catheter blockage, and has comparable effects to the loss of the Bcr/CflA trans-
porter on motility and ability to encrust urethral catheters. However, it should be noted that although our molec-
ular modelling predicts these drugs interact strongly with, and can potentially inhibit, the biofilm-associated 
Bcr/CflA transporter, and the effect of fluoxetine and thioridazine treatment generate phenotypes comparable to 
disruption of the Bcr/CflA gene, the effects of chemical EPIs are not certain to be restricted to a single specific 
pump, and there is much potential for the results obtained in this study to originate from a broader, more gen-
eralised interference with the P. mirabilis “effluxome”. In addition, the possibility that these drugs may also have 
effects on P. mirabilis unrelated to efflux inhibition cannot yet be fully excluded. Nonetheless, these data provide 
further support for efflux systems as a viable target for control of bacterial biofilm formation, and the Bcr/CflA 
MFS transporter in P. mirabilis in particular.
Further research will not only need to provide greater understanding of the specific transporters and their 
substrates affected by thioridazine and fluoxetine, but also how such EPIs may best be utilised to develop strat-
egies for control of CAUTI, or wider bacterial biofilm formation. The use of these drugs according to standard 
current clinical practice and prescribing approaches is unlikely to be feasible or useful for the control of CAUTI 
(for reasons relating to safety, efficacy, and pharmacokinetics), and the concentrations utilized in these laboratory 
studies are much higher than those normally achieved in body fluids such as urine in practice46–49. Nevertheless, 
there is considerable scope to explore localised delivery in the catheterized urinary tract, the use of combinations 
of EPIs, or the synergistic use of EPIs with antibiotics, which may yield strategies to deploy these drugs for CAUTI 
control. Moreover, regardless of the potential to utilize these drugs directly, they can nevertheless serve as valuable 
lead compounds to stimulate the development of new classes of anti-biofilm agents with novel modes of action.
Materials and Methods
Bacterial strains, media, and routine culture. General culture and media. Clinical isolates of Proteus 
mirabilis, Escherichia coli, and Pseudomonas aeruginosa from urinary tract infections used in this study were 
obtained from the Royal Sussex County Hospital, Bristol Southmeads Hospital, and the P. aeruginosa isolate from 
a collection described by De Soyza et al.50. All chemicals, reagents, and growth media were obtained from Fisher 
Scientific (United Kingdom), Sigma (United Kingdom), Oxoid (United Kingdom), or Tocris Bioscience (United 
Kingdom), unless otherwise stated. Bacteria were routinely cultured in Luria-Bertani (LB) medium (5 g/L yeast 
extract, 10 g/L tryptone, 10 g/L sodium chloride) at 37 °C with shaking or on LB solidified by the addition of 
15 g/L technical agar. For the isolation of single colonies of P. mirabilis and the suppression of swarming motility, 
strains were grown on LB agar without salt and 20 g/L technical agar.
Artificial urine. The artificial urine (AU) medium previously described by Stickler et al.26, was initially prepared 
as a 5x concentrated stock solution containing sodium disulfate (11.5 g/L), magnesium chloride (hexahydrate) 
(3.25 g/L), sodium chloride (23 g/L), trisodium citrate (3.25 g/L), sodium oxalate (0.1 g/L), potassium dihydrogen 
orthophosphate (14 g/L), potassium chloride (8 g/L), ammonium chloride (5 g/L), calcium chloride dihydrate 
(3.25 g/L), urea (125 g/L), gelatin (25 g/L), and tryptone soya broth (5 g/L). Stock solutions of urea and calcium 
chloride dihydrate were sterilized separately using a Nalgene Vacuum Filter System (0.45 μm nitrocelullose mem-
brane; Sartorius, United Kingdom), while other components were sterilized by autoclaving. For use in bladder 
models, all components were combined and diluted to 1x strength using sterile deionized water, with the final pH 
adjusted to 6.1.
Minimum inhibitory concentrations (MICs) of thioridazine and fluoxetine. The minimum con-
centrations of fluoxetine and thioridazine capable of inhibiting P. mirabilis growth were determined using a broth 
micro-dilution method. Wells containing LB broth with doubling dilutions of each drug were inoculated with 
1 × 105 CFU/mL log phase P. mirabilis cells, and incubated statically for 20 h at 37 °C. Growth was determined 
spectrophotometrically measuring the optical density at 600 nm (OD600), and the MIC was defined as the lowest 
concentration of compound that inhibited measurable growth.
Efflux inhibition assays. Assays for inhibition of efflux were modified from those originally described by 
Coldham et al.51. Overnight LB broth cultures were re-suspended in fresh broth at 1:100 dilution, and grown 
for a further 1.5 h with shaking. The cells were harvested by centrifugation, re-suspended in AU medium and 
adjusted to an OD600 of 0.6. The adjusted cell suspension was dispensed into a 96-well plate (50 µL/well) contain-
ing 50 µL AU supplemented with glucose (40 mM), Ethidium Bromide (EtBr; 10 µg/mL) as an efflux substrate, 
and sub-MIC levels of thioridazine or fluoxetine. Controls included background control with cell-free AU but 
with all other supplements and EPIs; cell suspensions with EtBr substrate but no EPI; and cell suspensions with 
EPIs but no EtBr substrate. Plates were sealed with breathable membranes to prevent evaporation and incubated 
at 37 °C with gentle rocking for 2 h. Controls to measure the highest accumulation of EtBr in each strain were also 
set up and consisted of 200 μL of each strain heated to 65 °C for 5 min in 1.5 mL centrifuge tubes to lyse the cells. 
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7: 12222  | DOI:10.1038/s41598-017-12445-w
Following incubation, fluorescence was measured at 540 nm excitation and 600 nm emission and relative accu-
mulation of EtBr (indicative of efflux inhibition) was calculated as: Fluorescence in EPI treated cells - fluorescence 
in background controls.
In vitro models of the catheterized urinary tract. Bladder models were conducted as originally 
described by Stickler et al.26, with minor modifications, and are illustrated in Figure S1. Models consist of a 
double-walled glass chamber (the bladder) maintained at 37 °C by a water jacket supplied from a circulating 
water bath. Size 14 French all-silicone Foley catheters (Bard, United Kingdom) were inserted into the bladder and 
retention balloons inflated with 10 mL sterile water. The catheter was attached to a drainage bag to form a sterile, 
closed drainage system. AU medium supplemented with sub-MIC levels of EPIs was supplied to the bladder at a 
constant flow rate of 0.75 mL/min. Bladder models were inoculated with 10 mL of a bacterial culture containing 
∼109 CFU/mL and bacterial cells were allowed to establish within the model for 1 h before flow was activated. 
The number of viable cells in the bladder residual urine and the pH of the medium were measured at the start and 
end of experiments.
Molecular modelling methods. Homology modelling. The structure of the Bcr/CflA efflux pump pro-
tein was generated by homology modelling using the I-TASSER webserver. The FASTA uniport code B4ET96 
of the amino acid sequence was applied, and the model with the highest C-score and TM-score was selected for 
the modelling study. The C-score and TM score for the generated model were 1.58 and 0.94, respectively. After 
homology modelling, the PDB structure was amended in the missing parts by Accelrys discovery studio 4.5 
software (Figure S2). Phyre2 (Protein Homology/analogY Recognition Engine V 2.0) was applied to provide a 
residue-wise profile, to assess the accuracy of the homology model (Figure S3).
Molecular docking. Molecular docking protocols are methods which predict the preferred orientation of a 
bound ligand to a target that forms a stable complex52,53. Knowledge of the preferred orientation may in turn be 
used to predict the strength of association or binding affinity between two molecules using, for example, scoring 
functions. AutoDock smina54, which uses the AutoDock Vina scoring function by default, was used for the blind 
molecular docking of the ligands thioridazine and fluoxetine to the Bcr/CflA, for finding the best binding site by 
exploring all probable binding cavities of the proteins. SIMNA was performed with default settings, which sam-
ples nine ligand conformations using the Vina docking routine of stochastic sampling. Then GOLD molecular 
docking55,56 was applied for the docking of thioridazine and fluoxetine to the SIMNA-located best binding site of 
the transporter, for performing flexible molecular docking. Based on the fitness function scores and ligand bind-
ing positions, the best-docked poses for the ligands were selected. The best docked pose has the highest fitness 
function score and the most negative energy.
The GOLD molecular docking procedure was performed by applying the GOLD protocol56 in the Accelrys 
Discovery Studio software. The Genetic Algorithm (GA) was used in GOLD ligand docking software to examine 
thoroughly the ligand conformational flexibility, along with the partial flexibility of the protein57. The maximum 
number of runs was set to 20 for the ligand, and the default parameters selected were 100 population size, 5 for the 
number of islands, 100,000 number of operations and 2 for the niche size. Default cut-off values of 2.5 Å (dH-X) 
for hydrogen bonds and 4.0 Å for the van-der-Waals distance were applied. When the top solutions attained the 
RMSD values within 1.5 Å, the GA docking was terminated.
Molecular dynamics (MD) simulations. After the molecular docking, 100-ns independent molecular dynamics 
simulations were performed for the complexes and the ligand-free protein, which were followed by MM-PBSA/
MM-GBSA calculations. All the MD simulations were carried out using the AMBER 12.0 package. Each sys-
tem was solvated by using an octahedral box of TIP3P water molecules. Periodic boundary conditions and the 
particle-mesh Ewald (PME) method were employed in the simulations58. The Particle Mesh Ewald (PME) method 
enabled us to calculate the ‘infinite’ electrostatics without truncating the parameters. During each simulation, all 
bonds in which the hydrogen atom was present were considered fixed, and all other bonds were constrained to 
their equilibrium values by applying the SHAKE algorithm59. The force field parameters for the ligand were gen-
erated by using the ANTECHAMBER module of the AMBER program. A cut-off radius of non-covalent interac-
tions was set to 12 Å for the proteins and complexes. Each minimization and equilibration phase was performed 
in two stages. In the first stage, ions and all water molecules were minimized for 500 cycles of steepest descent fol-
lowed by 500 cycles of conjugate gradient minimization. Afterwards, the whole system was minimized for a total 
of 2500 cycles without restraint, wherein 1000 cycles of steepest descent were followed by 1500 cycles of conjugate 
gradient minimization. In the second stage, the systems were equilibrated for 500 ps while the temperature was 
raised from 0 to 300 K, and then equilibration was performed without a restraint for 100 ps while the temperature 
was kept at 300 K. The sampling of reasonable configurations was conducted by running a 100 ns simulation with 
a 2 fs time step at 300 K and 1 atm pressure. A constant temperature was maintained by applying the Langevin 
algorithm, while the pressure was controlled by the isotropic position scaling protocol used in AMBER60. The 
time dependence of root-mean-square deviations (RMSD) (Å) for the backbone atoms relative to the starting 
structure during 100 ns MD simulations of both ligand-free and ligand-bound Bcr/CflA were calculated.
Swimming and swarming assays. Swarming motility was characterized on plates containing LB agar 
supplemented with sub-MIC levels of EPIs. A 10 μL drop of an overnight culture was inoculated onto the centre of 
each plate. The drops were allowed to soak into the agar at room temperature, and then the plates were incubated 
for 8 h at 37 °C. To assess swimming motility, 2 μL of an overnight culture was stabbed into the centre of soft LB 
agar motility plates (LB medium solidified with 0.15% agar), and incubated for 6 h at 37 °C. The distances that the 
bacteria migrated on both types of agar, from the point of inoculation, were measured in mm.
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Quantification of crystalline biofilm formation on catheter sections. The amount of calcium 
present on catheter sections removed from timed bladder model experiments (10 h) was quantified by flame 
photometry, as described previously (Holling et al.20). 1 cm sections of catheter were submerged in 2 mL of a 
solution of ammonium oxalate and oxalic acid (95% and 5% [vol/vol], respectively, from 0.1 M stock solutions). 
Submerged sections were subjected to vigorous mixing for 3 min, before incubation at room temperature for 
30 min. Catheter sections were then removed, and the remaining mixture centrifuged (3,000 × g for 10 min). The 
resulting supernatants were discarded, and pellets resuspended in 5 mL of perchloric acid (0.05 M), mixed thor-
oughly, centrifuged (3,000 × g for 2 min), and supernatants recovered. Levels of calcium dissolved in supernatants 
were quantified using a flame photometer (Flame Photometer 410; Corning) calibrated using calcium standards 
at 100, 75, 50, and 25 ppm.
Scanning electron microscopy of catheter cross sections. Biofilms formed on catheters recovered 
from timed models were visualized directly by scanning electron microscopy (SEM) as previously described by 
Holling et al.20. Catheter sections (1 cm) were mounted directly onto aluminum stubs using Leit adhesive carbon 
tabs (Agar Scientific, Stansted, United Kingdom), and stored overnight in a desiccator at room temperature. The 
following day, catheter sections were sputter coated with platinum using a Quorum Q150T ES system (Quorum 
Technologies, United Kingdom), and viewed using a Zeiss Evo LS15 microscope under high vacuum at an accel-
erating voltage of 5 kV and using a 5 quadrant backscatter detector (5Q-BSD).
Statistical Analyses. All statistical analysis was performed using Prism 7.0c for Mac OS X (GraphPad 
Software, Inc., USA). Data were analyzed using either Student’s t test or analysis of variance with the Bonferroni 
correction of multiple comparisons.
References
 1. Mobley, H. L. T. Virulence of Proteus mirabilis In Urinary tract infections, molecular pathogenesis and clinical management (ed 
Mobley, H. L. T & Warren, J. W.) 245–265 (ASM Press, Washington, DC. 1996).
 2. Stickler, D. J. Bacterial biofilms in patients with indwelling urinary catheters. Nat. Clin. Pract. Urol. 5, 598–608 (2008).
 3. Stickler, D. J. Clinical complications of urinary catheters caused by crystalline biofilms: something needs to be done. J. Intern. Med. 
276, 120–129 (2014).
 4. Stickler, D. J., Ganderton, L., King, J., Nettleton, J. & Winters, C. Proteus mirabilis biofilms and the encrustation of urethral catheters. 
Urol. Res. 21, 407–411 (1993).
 5. Jones, B. V., Mahenthiralingam, E., Sabbuba, N. A. & Stickler, D. J. Role of swarming in the formation of crystalline Proteus mirabilis 
biofilms on urinary catheters. J. Med. Microbiol. 54, 807–813 (2005).
 6. Jones, B. D. & Mobley, H. L. Genetic and biochemical diversity of ureases of Proteus, Providencia, and Morganella species isolated 
from urinary tract infection. Infect. Immun. 55, 2198–2203 (1987).
 7. Griffith, D. P., Musher, D. M. & Itin, C. Urease: the primary cause of infection-induced urinary stones. Invest. Urol. 13, 346–350 
(1976).
 8. Hedelin, H., Eddeland, A., Larsson, L., Pettersson, S. & Ohman, S. The composition of catheter encrustations, including the effects 
of allopurinol treatment. Br. J. Urol. 56, 250–254 (1984).
 9. Cox, A. J. & Hukins, D. W. L. Morphology of mineral-deposits on encrusted urinary catheters investigated by scanning electron-
microscopy. J. Urol. 142, 1347–1350 (1989).
 10. Holling, N. et al. Evaluation of environmental scanning electron microscopy for analysis of Proteus mirabilis crystalline biofilms in 
situ on urinary catheters. FEMS Microbiol. Lett. 355, 20–27 (2014).
 11. Dumanski, A. J., Hedelin, H., Edin-Liljegren, A., Beauchemin, D. & McLean, R. J. Unique ability of the Proteus mirabilis capsule to 
enhance mineral growth in infectious urinary calculi. Infect. Immun. 62, 2998–3003 (1994).
 12. Clapham, L., McLean, R. J. C., Nickel, J. C., Downey, J. & Costerton, J. W. The influence of bacteria on struvite crystal habit and its 
importance in urinary stone formation. J. Cryst. Growth 104, 475–484 (1990).
 13. Jacobsen, S. M., Stickler, D. J., Mobley, H. L. & Shirtliff, M. E. Complicated catheter-associated urinary tract infections due to 
Escherichia coli and Proteus mirabilis. Clin. Microbiol. Rev. 21, 26–59 (2008).
 14. Getliffe, K. A. The characteristics and management of patients with recurrent blockage of long-term urinary catheters. J Adv Nurs. 
20, 140–149 (1994).
 15. Kohler–Ockmore, J. & Feneley, R. C. L. Long-term catheterization of the bladder: prevalence and morbidity. Br. J. Urol. 77, 347–351 
(1996).
 16. Morgan, S. D., Rigby, D. & Stickler, D. J. A study of the structure of the crystalline biofilms that encrust and block silver Foley 
catheters. Urol. Res. 37, 88–93 (2009).
 17. Morris, N. S., Stickler, D. J. & Winters, C. Which indwelling urethral catheters resist encrustation by Proteus mirabilis biofilms? Br. 
J. Urol. 80, 58–63 (1997).
 18. Pikard, R. et al. Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term 
catheterisation in hospital: a multicentre randomised controlled trial. Lancet 380, 1927–1935 (2012).
 19. Kunin, C. M. Urinary Tract Infections: Detection, Prevention and Management, 5th edn (ed. Pine, J.) 226–278 (Baltimore: Williams 
& Wilkins, 1997).
 20. Holling, N. et al. Elucidating the genetic basis of crystalline biofilm formation in Proteus mirabilis. Infect. Immun. 82, 1616–1626 
(2014).
 21. Munoz-Bellido, J. L., Munoz-Criado, S. & Garcìa-Rodrìguez, J. A. Antimicrobial activity of psychotropic drugs: selective serotonin 
reuptake inhibitors. Int. J. Antimicrob. Agents 14, 177–180 (2000).
 22. Kaatz, G. W., Moudgal, V. V., Seo, S. M., Hansen, J. B. & Kristiensen, J. E. Phenothiazines and thioxanthenes inhibit multidrug efflux 
pump activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 719–726 (2003).
 23. Kvist, M., Hancock, V. & Klemm, P. Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl. Environ. Microbiol. 74, 
7376–7382 (2008).
 24. Amaral, L. et al. Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB. 
In Vivo 24, 409–424 (2010).
 25. Bohnert, J. A., Szymaniak-Vits, M., Schuster, S. & Kern, W. V. Efflux inhibition by selective serotonin reuptake inhibitors in 
Escherichia coli. J. Antimicrob. Chemother. 66, 2057–2060 (2011).
 26. Stickler, D. J. & Hughes, G. Ability of Proteus mirabilis to swarm over urethral catheters. Eur. J. Clin. Microbiol. Infect. Dis. 18, 
206–208 (1999).
 27. Nzakizwanayo, J. et al. Bacteriophage therapy can prevent encrustation and blockage of urinary catheters by. Proteus mirabilis. 
Antimicrob. Agents Chemother. 60, 1530–1536 (2016).
www.nature.com/scientificreports/
13Scientific RepoRts | 7: 12222  | DOI:10.1038/s41598-017-12445-w
 28. Baugh, S., Phillips, C. R., Ekanayaka, A. S., Piddock, L. J. & Webber, M. A. Inhibition of multidrug efflux as a strategy to prevent 
biofilm formation. J. Antimicrob. Chemother. 69, 673–681 (2014).
 29. Dasgupta, A. et al. Thioridazine protects the mouse from a virulent infection by Salmonella enterica serovar Typhimurium 74. Int. J. 
Antimicrob. Agents 35, 174–176 (2009).
 30. Lin, Y. T., Huang, Y. W., Chen, S. J., Chang, C. W. & Yang, T. C. The SmeYZ efflux pump of Stenotrophomonas maltophilia contributes 
to drug resistance, virulence-related characteristics, and virulence in mice. Antimicrob. Agents Chemother. 59, 4067–4073 (2015).
 31. Jerse, A. E. et al. A gonococcal efflux pump system enhances bacterial survival in a female mouse model of genital tract infection. 
Infect. Immun. 71, 5576–5582 (2003).
 32. Ding, Y., Fu, Y., Lee, J. C. & Hoopera, D. C. Staphylococcus aureus NorD, a putative efflux pump coregulated with the Opp1 
oligopeptide permease, contributes selectively to fitness in vivo. J. Bacteriol. 194, 6586–6593 (2012).
 33. Maseda, H. et al. Enhancement of the mexAB-oprM efflux pump expression by a quorum-sensing autoinducer and its cancellation 
by a regulator, MexT, of the mexEF-oprN efflux pump operon in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 48, 
1320–1328 (2004).
 34. Webber, M. A. The global consequence of disruption of the AcrAB-TolC efflux pump in Salmonella enterica includes reduced 
expression of SPI-1 and other attributes required to infect the host. J. Bacteriol. 191, 4276–4285 (2009).
 35. Truong-Bolduc, Q. C. et al. Role of the Tet38 Role of the Tet38 Efflux Pump in Staphylococcus aureus Internalization and Survival in 
Epithelial Cells. Infect. Immun. 83, 4362–4372 (2015).
 36. Buckner, M. M. C. et al. Beyond antimicrobial resistance: evidence for a distinct role of the AcrD efflux pump in Salmonella biology. 
MBio 7, e01916–16, https://doi.org/10.1128/mBio.01916-16 (2016).
 37. Zhang, L. & Mah, T. F. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J. Bacteriol. 190, 4447–4452 
(2008).
 38. Matsumura, K., Furukawa, S., Ogihara, H. & Morinaga, Y. Roles of multidrug efflux pumps in the biofilm formation of Escherichia 
coli K12. Biocontrol Sci. 16, 69–72 (2011).
 39. Soto, S. M. Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm. Virulence 4, 223–229 (2013).
 40. Sun, J., Deng, Z. & Yan, A. Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. Biochem. 
Biophys. Res. Commun. 453, 254–267 (2014).
 41. Martinez, J. L. et al. Functional role of bacterial multidrug efflux pumps in microbial natural ecosystems. FEMS Microbiol. Rev. 33, 
430–449 (2009).
 42. Vargas, P. et al. Plant flavonoids target Pseudomonas syringae pv. tomato DC3000 flagella and type III secretion system. Environ. 
Microbiol. Rep. 5, 841–850 (2013).
 43. Jones, B. V., Young, R., Mahenthiralingam, E. & Stickler, D. J. Ultrastructure of Proteus mirabilis swarmer cell rafts and role of 
swarming in catheter-associated urinary tract infection. Infect. Immun. 72, 3941–3950 (2004).
 44. O’Toole, G. A. & Kolter, R. Flagellar and twitching motility are necessary for biofilm development. Mol. Microbiol. 30, 295–304 
(1998).
 45. Pratt, L. A. & Kolter, R. Genetic analysis of Escherichia coli biofilm formation: roles of flagella, motility, chemotaxis and type I pili. 
Mol. Microbiol. 30, 285–293 (1998).
 46. Ng, C. H. & Crammer, J. L. Measurement of thioridazine in Blood and Urine. Br. J. Clin. Pharmacol. 4, 173–183 (1977).
 47. PharmGBK.org for fluoxetine (accessed 26/06/2017): https://www.pharmgkb.org/pathway/PA161749012#tabview=tab0&subtab.
 48. PharmGBK.org for thioridazine (accessed 26/06/2017): https://www.pharmgkb.org/chemical/PA451666#tabview=tab0&subtab=32.
 49. Johnson, R. D., Lewis, R. J. & Angier, M. K. The Distribution of fluoxetine in human fluids and tissues. J. Anal. Toxicol. 31, 409–414 
(2007).
 50. De Soyza, A. et al. Developing an international Pseudomonas aeruginosa reference panel. MicrobiologyOpen 2, 1010–1023, https://
doi.org/10.1002/mbo3.141 (2013).
 51. Coldham, N. G., Webber, M., Woodward, M. J. & Piddock, L. J. A 96-well plate fluorescence assay for assessment of cellular 
permeability and active efflux in Salmonella enterica serovar Typhimurium and Escherichia coli. J. Antimicrob. Chemother. 65, 
1655–1663 (2010).
 52. Lengauer, T. & Rarey, M. Computational methods for biomolecular docking. Curr. Opin. Struct. Biol. 6, 402–406 (1996).
 53. Chen, Y. C. Beware of docking! Trends Pharmacol. Sci. 36, 78–95 (2015).
 54. Koes, D. R., Baumgartner, M. P. & Camacho, C. J. Lessons learned in empirical scoring with smina from the CSAR 2011 
benchmarking exercise. J. Chem. Inf. Model. 53, 1893–1904 (2013).
 55. Jones, G., Willett, P. & Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. 
J. Mol. Biol. 245, 43–53 (1995).
 56. Jones, G., Willett, P., Glen, R. C., Leach, A. R. & Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. 
Mol. Biol. 267, 727–748 (1995).
 57. Nissink, J. W. et al. A new test set for validating predictions of protein-ligand interaction. Proteins 49, 457–471 (2002).
 58. Darden, T., York, D. & Pedersen, L. Particle mesh Ewald - an N·log(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 
10089–10092 (1993).
 59. Ryckaert, J. P., Ciccotti, G. & Berendsen, H. J. C. Numerical integration of the cartesian equations of motion of a system with 
constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 23, 327–341 (1977).
 60. Case, D. A. et al. The Amber biomolecular simulation programs. J. Comput. Chem. 26, 1668–1688 (2005).
Acknowledgements
This study was primarily supported by the Dunhill Medical Trust (DMT), proving funding to J.N., P.S., B.A.P., 
L.M.B. and B.V.J. under grant number R394/1114. H.P., B.V.J., M.J.S., and J.N. are also supported by the Medical 
Research Council (Grants MR/P015956/1 and MR/N006496/1). Molecular docking simulations were supported 
by the King’s College London High Performance Computing Facility (Kings HPC3, Ada Cluster).
Author Contributions
B.V.J., L.M.B., J.N. and B.A.P. conceived the study, B.V.J., M.J.S., J.N., C.K.H., and R.K.M. designed the 
experiments, J.N., P.S., J.S., J.A.H., H.P., C.D., J.P.S. conducted the experiments. All authors contributed to 
protocol development, and analysis and interpretation of the data. B.V.J. and J.N. wrote the manuscript and all 
authors edited the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-12445-w.
Competing Interests: The authors declare that they have no competing interests.
www.nature.com/scientificreports/
1 4Scientific RepoRts | 7: 12222  | DOI:10.1038/s41598-017-12445-w
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
